As of Feb 28, 2025
Tema Neuroscience and Mental Health ETF (NASDAQ: MNTL)
Ticker | Name | Share % | |
---|---|---|---|
VRTX | Vertex Pharmaceuticals Inc | 10.08% | |
REGN | Regeneron Pharmaceuticals, Inc. | 7.71% | |
LLY | Eli Lilly & Co. | 4.61% | |
ALNY | Alnylam Pharmaceuticals Inc. | 4.47% | |
AS | Argenx Se Spon Adr Each Rep 1 Ord Shs | 5.08% | |
NBIX | Neurocrine Biosciences Inc | 3.72% | |
DNLI | Denali Therapeutics Inc | 4.18% | |
BIIB | Biogen Inc. | 3.21% | |
IL | Teva Pharmaceutical Industries Ltd Sponsored Adr | 4.34% | |
CRNX | Crinetics Pharmaceuticals Inc Com | 4.28% | |
SYK | Stryker Corp | 2.82% |
The MNTL ETF is currently trading at $22.78, which represents a 1.95% change. Over the past 52 weeks, the ETF has traded as high as $27.66 and as low as $22.35.
The expense ratio of MNTL is 0.75%. This represents the annual fee that all funds or ETFs charge their shareholders.
The total Assets Under Management (AUM) for MNTL is 10.31M. This represents the total market value of the assets managed by the ETF.
MNTL follows a Mid Cap Blend investment style.
The top holdings of MNTL include: VRTX (10.08%), REGN (7.71%), LLY (4.61%), ALNY (4.47%), AS (5.08%). These represent the largest positions in the ETF's portfolio.
Average daily volume data for MNTL is currently not available.